Use of GLP-1 drugs early in pregnancy should not cause alarm, analysis suggests

A large data analysis from the Harvard T.H. Chan School of Public Health suggests that using GLP-1 drugs like Ozempic or Mounjaro early in the first trimester of pregnancy is not a cause for alarm. The study found no statistically significant increase in the risk of non-live births for women who continued these medications after conception compared to those who did not.

How did the Harvard study analyze GLP-1 exposure?

Researchers analyzed 3,572 pregnancies in women who used GLP-1 drugs prior to conception. This group included 1,467 women with type 2 diabetes. The study compared outcomes for those who continued using medications into the first trimester against those who stopped.

The data showed the risk for non-live birth was 29.7% for those who continued the medication, compared to 27.1% for those who did not. According to the researchers, this difference was not statistically significant.

The analysis also looked at major congenital malformations and birth weight. Staying on the drugs did not appear to substantially increase the risks for high or low birth weight or malformations, though the researchers noted these specific estimates were imprecise.

Did You Know? Tirzepatide, sold as Zepbound and Mounjaro, has been found to compromise the absorption of oral contraceptives, which can contribute to accidental pregnancy.

Why is this finding significant for women’s health?

GLP-1 medications, including Novo Nordisk’s semaglutide (Ozempic and Wegovy) and Eli Lilly’s tirzepatide (Zepbound and Mounjaro), are not recommended during pregnancy. Their safety for the fetus is currently unknown, and animal studies have suggested potential risks.

Are GLP-1 safe for pregnancy?

However, these drugs can improve fertility in some obese women by enhancing insulin sensitivity and reducing weight. This creates a scenario where women may become pregnant while on the medication before they realize it.

Study leader Dr. Jeremy Brown stated that these findings provide reassurance regarding unintentional exposure early in pregnancy. Senior author Dr. Sonia Hernandez-Diaz added that while safety cannot be guaranteed, women who used the drugs before discovering their pregnancy “needn’t panic.”

Expert Insight: Samantha Carter notes that the stakes here involve balancing clinical caution with patient anxiety. While the data offers a psychological safety net for accidental exposure, the lack of a “guarantee” on safety means the medical community must maintain a strict boundary between unintentional use and planned pregnancy.

What happens next for GLP-1 pregnancy guidelines?

Current medical guidelines advise women to stop taking GLP-1 drugs at least one or two months before attempting pregnancy. Dr. Sonia Hernandez-Diaz clarified that this study cannot on its own change those existing recommendations.

Future clinical guidance may continue to emphasize following label instructions and clinician advice. Because the study focused on early exposure, the medical community could continue to monitor long-term outcomes to further refine safety profiles.

Patients planning pregnancy are likely to be encouraged to maintain strict adherence to the recommended cessation window to avoid any potential risks identified in animal studies.

Frequently Asked Questions

Are GLP-1 drugs recommended for use during pregnancy?
No. They are not recommended because their safety for the fetus is unknown and animal studies have suggested potential risks.

Did the Harvard study find a significant increase in non-live births?
No. The risk was 29.7% with medication continuation versus 27.1% without, a difference that was not deemed statistically significant.

When should a woman stop taking GLP-1 drugs if she plans to get pregnant?
Medical guidelines advise stopping these medications at least one or two months before pregnancy.

How do you feel this new data impacts the conversation around weight-loss medications and reproductive health?